Thirty two preschool children were entered into a double blind, placebo controlled study using intermittent budesonide to treat viral induced wheeze. Active treatment was either 800 tg twice a day via a spacer or 1600 jig twice a day via a spacer and facemask in those children too young to use a mouthpiece. Treatment was started at the onset of an upper respiratory tract infection and continued for seven days or until symptoms had resolved for 24 hours. Each child remained in the study until they had completed using one pair of budesonide and placebo inhalers in random order without the need for additional oral prednisolone.
G Connett, W Lenney Abstract Thirty two preschool children were entered into a double blind, placebo controlled study using intermittent budesonide to treat viral induced wheeze. Active treatment was either 800 tg twice a day via a spacer or 1600 jig twice a day via a spacer and facemask in those children too young to use a mouthpiece. Treatment was started at the onset of an upper respiratory tract infection and continued for seven days or until symptoms had resolved for 24 hours. Each child remained in the study until they had completed using one pair of budesonide and placebo inhalers in random order without the need for additional oral prednisolone.
Twenty five children completed 28 treatment pairs. AlU 25 families were asked to express a preference after completing their first treatment pair: 12 preferred budesonide and six preferred placebo; seven had no preference. Symptom scores were compared in 17 treatment pairs that were completed without the need for oral prednisolone. Mean day and night time wheeze in the first week after infection were significantly lower in those receiving budesonide.
Intermittent inhalation of budesonide can modify the severity of wheezing in preschool children developing asthma after viral respiratory infections but improvements were modest with the doses used in this study. Eighteen of the 25 families expressed a preference after they had completed using the first pair of inhalers. Twelve preferred budesonide and six preferred placebo. This increased preference for budesonide was significant (p<005).
Eleven of the 28 treatment pairs were complicated by the use of prednisolone. This was given for symptoms after one episode in 10 children and one child received prednisolone after both inhalers. Two of these children required hospital admission. In the 10 children who were given prednisolone once, eight had received placebo and two had received budesonide. This difference was not significant when tested for using McNemar's test for paired data (with or without Yates's correction) because of the small numbers available for analysis.
There were 17 treatment pairs for which no intervention with oral steroids was necessary. The mean (SD) number of days on which study medication was given was similar in the two groups: budesonide 5.5 (1 4) Although this study provides statistical evidence for these conclusions, the benefits of treatment were not always clinically obvious and parental preferences were often marginal. Ensuring that parents accurately followed the treatment protocol was time consuming, and necessitated repeated explanations and checks that inhalers were used correctly. In most cases some lower respiratory symptoms were present by 24 to 36 hours after the onset of an URTI. Upper respiratory symptoms were similar in each episode. There were striking intrasubject similarities in the reported patterns of cough and wheeze for each treatment pair, but intersubject illnesses varied widely.
During the study there were fewer documented episodes of URTIs than the number reported in the six months before starting. The mean number of infective exacerbations in the first six months of the study was 2-11 compared with the reported mean of 2-93 over the six months before the study. The difference between the means was 0-82, with a 95% confidence interval of 0-288 to 1-34 (p<0.001). In many cases the first six months of the study included late autumn and winter when colds are more frequent. This suggests that either the frequency of respiratory illness decreased during the study or that parents tended to exaggerated when recollecting their child's symptoms.
The management of intermittent wheeze remains problematic. Complete prevention of asthma symptoms is only conceivable if treatment is given early during upper respiratory symptoms. This is often not achievable because of the time it takes for parents to consult the doctors. Perhaps larger doses of inhaled steroid would be more effective than the doses we have used. The amount of drug reaching the airways using a spacer and facemask is likely to be imprecise and treatment failure was more common when this system was used. This might be due to unresponsiveness to steroids in the younger age group or problems with the delivery system. A study using an alternative spacer and mask has suggested that less than 1% of delivered doses reach the lungs.'0 The doses chosen for the study were quite empirical, although budesonide, 200-400 [tg twice a day through the same delivery system can alleviate chronic persistent asthma in the same age group (unpublished data).
Preschool children with asthma are placing increasing demands on hospital and general practice services." 12 Heterogenous patterns of wheeze in this age group make it difficult to apply the lessons from studies in older asthmatics.'3 Increasing awareness of the different subgroups of young wheezy children should encourage the further use of novel therapeutic strategies specific to different patterns of symptoms.
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